(5-amino-1-m-tolyl-1H-pyrazole-4-carboxamide) | 1171627-74-9

• 英文名称: (5-amino-1-m-tolyl-1H-pyrazole-4-carboxamide)
• 英文别名: 5-amino-1-m-tolyl-1H-pyrazolo-4-carboxylic acid amide；5-amino-1-(3-methylphenyl)-1H-pyrazole-4-carboxamide；5-amino-1-(3-methylphenyl)pyrazole-4-carboxamide
• CAS: 1171627-74-9
• 化学式: C₁₁H₁₂N₄O
• mdl: MFCD11986603
• 分子量: 216.242
• InChiKey: UQCDEDLRNWOESG-UHFFFAOYSA-N

物化性质

• 沸点：
  440.5±35.0 °C(Predicted)
• 密度：
  1.36±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  86.9
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] COMBINATION THERAPY FOR TREATING MPS1<br/>[FR] POLYTHÉRAPIE POUR LE TRAITEMENT DE LA MPS1
  申请人：GAIN THERAPEUTICS SA

  公开号：WO2021156774A1

  公开（公告）日：2021-08-12

  The application is directed to compounds of formula (I) and their salts and solvates, wherein B, R1, R2, R3, R3', R4, R4', and R5 are as set forth in the specification, as well as to methods for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of, e.g., MPS1, optionally in combination with α-L-iduronidase or an analog or variant thereof, e.g., laronidase.

  该申请涉及公式(I)化合物及其盐和溶剂化合物，其中B、R1、R2、R3、R3'、R4、R4'和R5如规范中所述，以及其制备方法、含有相同化合物的药物组合物，以及用于治疗和/或预防MPS1等疾病的方法，可选地与α-L-异硫酸酶或其类似物或变体（例如，laronidase）结合使用。
• NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS
  申请人：Konakanchi Durga Prasad

  公开号：US20100298351A1

  公开（公告）日：2010-11-25

  The invention relates to substituted pyrazolo[3,4-d]pyrimidine derivatives of the Formula-(I), or pharmaceutically-acceptable salts thereof, which possess anti-proliferative activity such as anti-cancer activity and are accordingly useful in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of substituted pyrazolo[3,4-d]pyrimidine derivatives, to pharmaceutical compositions containing the compound and to its use in the manufacture of medicaments for the production of an anti-proliferative effect in a warm-blooded animal such as man.

  该发明涉及式(I)的取代吡唑并[3,4-d]嘧啶衍生物或其药学上可接受的盐，其具有抗增殖活性，如抗癌活性，并因此在人体或动物体的治疗方法中有用。该发明还涉及制备取代吡唑并[3,4-d]嘧啶衍生物的方法，含有该化合物的药物组合物，以及其在制造药物时用于在诸如人类之类的温血动物体内产生抗增殖效果的用途。
• NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI -CANCER AGENTS
  申请人：Natco Pharma Limited

  公开号：EP2247596A2

  公开（公告）日：2010-11-10
• COMBINATION THERAPY FOR TREATING MPS1
  申请人：Gain Therapeutics SA

  公开号：EP4100015A1

  公开（公告）日：2022-12-14
• US8349847B2
  申请人：——

  公开号：US8349847B2

  公开（公告）日：2013-01-08